A subsequent analysis conducted with the same model, showed that immune PD-L1 expression in the tumor was increased after sorafenib treatment, suggesting a promising role for a triple combination therapy with AMD3100, sorafenib and anti-PD-1 antibody [79]. This evidence concerns the gene CD274 and neoplasm.